My First Million
The best business ideas come from noticing what's working and doing it better, faster, or for a different audience.
GLP-1 Drugs Expanding Beyond Weight Loss
Timeframe: 2-5 years for mainstream adoption of expanded use cases
What's Changing
GLP-1 drugs like Ozempic are showing effects beyond weight loss, potentially treating addiction, alcoholism, and other craving-based behaviors.
Driving Forces
Successful weight loss outcomes creating broader experimentation
Early reports of reduced alcohol and substance cravings
Growing understanding of GLP-1 receptors in brain reward systems
Massive market demand driving research investment
Winners
- Pharmaceutical companies with GLP-1 drug portfolios
- Healthcare providers specializing in addiction treatment
- Companies creating complementary behavioral health tools
- Insurance companies if addiction treatment costs decrease
Losers
- Traditional weight loss industry
- Food companies dependent on processed/craving-driven consumption
- Potentially alcohol and tobacco industries
- Traditional addiction treatment centers
How to Position Yourself
Build complementary tools and services around GLP-1 usage
Create content and education around proper usage
Develop behavioral tracking apps for GLP-1 users
Focus on the expanding use cases beyond weight loss
Early Signals to Watch
Example Implementation
“Create behavioral tracking app specifically for GLP-1 users to monitor not just weight but also alcohol consumption, food cravings, and other addictive behaviors.”